GLP1R and obesity disorder: The issue of obesity and insulin resistance prompted the design of a number of studies investigating the effects of antidiabetic drugs in PCOS, as reported in recent and very exhaustive reviews on the available clinical trials on glucagon-like peptide 1 receptor agonists (GLP-1RA) in PCOS [21, 23, 24].